OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive ...

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

Efficacy outcomes 12 months after initiation of darolutamide ... testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic castration resistant prostate cancer ...

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results ...

Beyond BRCA, understanding HR gene interactions and alternative pathways is crucial for refining PARPi efficacy and developing precise strategies for advanced, recurrent, and refractory OC patients.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The pill is over 99% effective with perfect use and about 91% effective with typical use. Efficacy data is generally combined for combination and progestin-only pills. In general, the progestin ...